Kalyani Narra
Hematology & Oncology · Pottstown, PANPI 1104016674
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,565 of the $9,428 with a category attached, or 80.2%. 22 manufacturers reported payments, led by AstraZeneca at 37.6% of the total. Reporting peaked in 2021 at $6,697 and has fallen 95.9% since, to $275 in 2025.
Across 50 payments — averaging $188.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$3K
- Daiichi Sankyo Inc.$550
- Astellas Pharma US Inc$515
- Sanofi-aventis U.S. LLC$350
- Cardinal Health 110 LLC$275
- plus $732 from 16 others
Across 14 payments — averaging $26,523 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$216K
- Genentech, Inc.$77K
- Bristol Myers Squibb$41K
- Merck$35K
- E.r. Squibb & Sons, L.L.C.$3K
What the payments were for
- Consulting fees$7,56580%
- Speaking & faculty fees$1,39515%
- Food & beverage$3314%
- Education$1381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 4 | $3,542 |
| GSK | 4 | $3,465 |
| Daiichi Sankyo Inc. | 1 | $550 |
| Astellas Pharma US Inc | 2 | $515 |
| Sanofi-aventis U.S. LLC | 1 | $350 |
| Cardinal Health 110 LLC | 1 | $275 |
| Novocure GmbH | 1 | $200 |
| Pfizer | 15 | $132 |
| Sanofi | 3 | $95 |
| Johnson & Johnson | 3 | $45 |
| Merck | 2 | $40 |
| Novartis | 2 | $37 |
| Boston Scientific | 1 | $32 |
| Genentech USA, Inc. | 2 | $28 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $17 |
| Bristol Myers Squibb | 1 | $17 |
| Amgen | 1 | $17 |
| Gilead | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,428 in reported general payments places this provider in the 75th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 31 | $447,784 |
| RevlimidLenalidomide | 19 | $342,683 |
| Lenalidomide | 22 | $301,629 |
| Abiraterone Acetate | 18 | $116,347 |
| BosulifBosutinib | 12 | $69,874 |
| EliquisApixaban | 36 | $40,823 |
| ValacyclovirValacyclovir Hcl | 34 | $2,217 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $1,765 |
| Ondansetron OdtOndansetron | 25 | $1,396 |
| Anastrozole | 74 | $1,197 |
| Prochlorperazine Maleate | 50 | $1,172 |
| Sucralfate | 14 | $861 |
| Potassium Chloride | 34 | $684 |
| Oxycodone Hcl | 13 | $599 |
| Gabapentin | 27 | $446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio, Olanzapine | $12 | $447,91543 claims |
| Bristol Myers SquibbRevlimid | $17 | $342,68319 claims |
| PfizerBosulif, Eliquis | $132 | $110,69748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Pottstown
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.